C4 Therapeutics Stock Cash And Equivalents
| CCCC Stock | USD 3.94 0.08 2.07% |
C4 Therapeutics fundamentals help investors to digest information that contributes to C4 Therapeutics' financial success or failures. It also enables traders to predict the movement of CCCC Stock. The fundamental analysis module provides a way to measure C4 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to C4 Therapeutics stock.
CCCC | Cash And Equivalents |
C4 Therapeutics Company Cash And Equivalents Analysis
C4 Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current C4 Therapeutics Cash And Equivalents | 307.78 M |
Most of C4 Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, C4 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CCCC Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for C4 Therapeutics is extremely important. It helps to project a fair market value of CCCC Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since C4 Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of C4 Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of C4 Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
CCCC Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, C4 Therapeutics has 307.78 M in Cash And Equivalents. This is 62.51% lower than that of the Biotechnology sector and 31.16% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 88.61% higher than that of the company.
CCCC Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses C4 Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of C4 Therapeutics could also be used in its relative valuation, which is a method of valuing C4 Therapeutics by comparing valuation metrics of similar companies.C4 Therapeutics is currently under evaluation in cash and equivalents category among its peers.
C4 Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of C4 Therapeutics from analyzing C4 Therapeutics' financial statements. These drivers represent accounts that assess C4 Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of C4 Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.4B | 1.5B | 288.3M | 280.5M | 322.5M | 306.4M | |
| Enterprise Value | 1.3B | 1.4B | 345.7M | 224.9M | 258.6M | 245.7M |
C4 Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, C4 Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to C4 Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
CCCC Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (1.84) % | ||||
| Current Valuation | 83.93 M | ||||
| Shares Outstanding | 70.59 M | ||||
| Shares Owned By Insiders | 11.42 % | ||||
| Shares Owned By Institutions | 91.45 % | ||||
| Number Of Shares Shorted | 8.6 M | ||||
| Price To Book | 1.12 X | ||||
| Price To Sales | 8.26 X | ||||
| Revenue | 20.76 M | ||||
| Gross Profit | (74.85 M) | ||||
| EBITDA | (122.1 M) | ||||
| Net Income | (132.49 M) | ||||
| Cash And Equivalents | 307.78 M | ||||
| Cash Per Share | 6.29 X | ||||
| Total Debt | 70.98 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 6.90 X | ||||
| Book Value Per Share | 3.44 X | ||||
| Cash Flow From Operations | (106.84 M) | ||||
| Short Ratio | 4.24 X | ||||
| Earnings Per Share | (1.71) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 16.38 | ||||
| Number Of Employees | 145 | ||||
| Beta | 3.06 | ||||
| Market Capitalization | 278.12 M | ||||
| Total Asset | 376.45 M | ||||
| Retained Earnings | (528.38 M) | ||||
| Working Capital | 228.42 M | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 49 K | ||||
| Net Asset | 376.45 M |
About C4 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze C4 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out C4 Therapeutics Piotroski F Score and C4 Therapeutics Altman Z Score analysis. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share | Quarterly Revenue Growth 0.387 | Return On Assets | Return On Equity |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.